Foremost, efforts center on promoting agonistic STING responses in the tumor microenvironment (TME), a strategy that has shown promising potential in multiple preclinical models against solid tumors and hematological malignancies (Chin et al., 2023; Guo and Huang, 2022; Li et al., 2021). Here, STING1 is linked to neoplasm.